Locations:
Search IconSearch

Dr. Robert Fox Receives Innovation Award for Advances in Progressive Multiple Sclerosis (Video)

Honor recognizes imaging and therapeutic insights behind slowing of brain atrophy

Treatments abound for the relapsing form of multiple sclerosis (MS), but virtually no therapies have been shown to slow the progressive form that the disease takes in its later stages.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

At least that was the case before Cleveland Clinic neurologist Robert J. Fox, MD, identified an asthma medication, ibudilast, as a potential treatment for progressive MS after it had failed in an earlier study for relapsing MS. His idea to apply the agent to progressive MS resulted in the multicenter SPRINT-MS study (N Engl J Med. 2018;379:846-855), which demonstrated an unprecedented 48 percent slowing in progression of whole brain atrophy with ibudilast therapy.

“The stroke of genius was Dr. Fox’s ability to find a possible success in a prior failure and to redirect towards a new clinical trial that has the potential to benefit countless patients with multiple sclerosis,” says Andre Machado, MD, PhD, Chair of Cleveland Clinic’s Neurological Institute.

That resourceful inventiveness is a key reason Dr. Fox, who serves as Vice Chair for Research in the Neurological Institute, has been named the recipient of Cleveland Clinic’s 2018 Sones Innovation Award. The selection committee also cited Dr. Fox’s leadership of a team of Cleveland Clinic imaging physicists and engineers to develop a collection of innovative, complex imaging techniques to provide imaging biomarkers for measuring response to therapy in the SPRINT-MS trial.

“These techniques are the most advanced imaging modalities ever deployed in a multicenter neurological clinical trial,” Dr. Machado observes, “and they have potential to accelerate development of therapies for other neurodegenerative diseases as well.”

The award won by Dr. Fox recognizes achievements that continue the tradition of pioneering Cleveland Clinic cardiologist F. Mason Sones, MD, to advance innovation in the service of improved patient care.

Advertisement

The three-and-a-half-minute video below shares more of the story behind Dr. Fox’s innovative work.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad